| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
STOK
Stoke Therapeutics
|
Jun 02, 2026 | BUY |
Strong Buy
+25.1% avg upside
18 analysts
|
— | +4.6% |
|
SPTX
Seaport Therapeutics, Inc.
|
May 27, 2026 | BUY |
Strong Buy
+95.4% avg upside
4 analysts
|
$35.00
92.71% Upside
|
· |
|
ACIU
AC Immune SA
|
Apr 07, 2026 | BUY |
Strong Buy
+233.3% avg upside
5 analysts
|
— | -10.3% |
|
ALKS
Alkermes
|
Mar 31, 2026 | HOLD |
Strong Buy
-17.5% avg upside
34 analysts
|
— | +28.2% |
|
SGP
SpyGlass Pharma
|
Mar 03, 2026 | BUY |
Strong Buy
+141.9% avg upside
5 analysts
|
$42.00
124.59% Upside
|
-30.1% |
|
MANE
Veradermics, Incorporated
|
Mar 02, 2026 | BUY |
Strong Buy
+31.9% avg upside
6 analysts
|
$75.00
20.15% Downside
|
· |
|
NMRA
Neumora Therapeutics, Inc.
|
Jan 11, 2026 | BUY |
Strong Buy
+422.4% avg upside
11 analysts
|
$8.00
429.82% Upside
|
-17.1% |
|
BHVN
Biohaven Ltd.
|
Dec 25, 2025 | BUY |
Strong Buy
+87.5% avg upside
25 analysts
|
$15.00
10.62% Upside
|
+21.7% |
|
MPLT
MapLight Therapeutics, Inc.
|
Nov 21, 2025 | BUY |
Strong Buy
+32.5% avg upside
11 analysts
|
$30.00
4.18% Upside
|
+94.1% |
|
OVID
Ovid Therapeutics
|
Nov 17, 2025 | BUY |
Strong Buy
+108.4% avg upside
17 analysts
|
$5.00
120.30% Upside
|
+102.3% |
|
BLTE
Belite Bio, Inc. ADR
|
Oct 15, 2025 | BUY |
Strong Buy
+25.0% avg upside
10 analysts
|
$85.00
41.88% Downside
|
+70.1% |
|
OCS
Oculis Holding
|
Oct 09, 2025 | BUY |
Strong Buy
+241.9% avg upside
11 analysts
|
$50.00
345.68% Upside
|
-45.8% |
|
ACAD
ACADIA Pharmaceuticals
|
Oct 07, 2025 | BUY |
Strong Buy
+66.0% avg upside
42 analysts
|
$30.00
38.70% Upside
|
+0.3% |
|
AMLX
Amylyx Pharmaceuticals Inc
|
Oct 07, 2025 | BUY |
Strong Buy
+46.8% avg upside
13 analysts
|
$20.00
27.55% Upside
|
+13.9% |
|
EOLS
Evolus
|
Oct 07, 2025 | BUY |
Strong Buy
+116.3% avg upside
9 analysts
|
— | +7.7% |
|
AXSM
Axsome Therapeutics
|
Oct 07, 2025 | BUY |
Strong Buy
-10.6% avg upside
28 analysts
|
— | +112.3% |
|
XENE
Xenon
|
Oct 07, 2025 | BUY |
Strong Buy
+19.0% avg upside
28 analysts
|
— | +33.8% |
|
JAZZ
Jazz Pharmaceuticals
|
Oct 07, 2025 | BUY |
Strong Buy
-1.8% avg upside
35 analysts
|
$215.00
4.23% Downside
|
+67.9% |
|
BIIB
Biogen
|
Oct 07, 2025 | BUY |
Strong Buy
+25.1% avg upside
51 analysts
|
— | +30.5% |
|
LBRX
LB Pharmaceuticals, Inc.
|
Oct 06, 2025 | BUY |
Strong Buy
+50.1% avg upside
7 analysts
|
$34.00
13.26% Upside
|
+84.2% |
|
NBIX
Neurocrine
|
Sep 23, 2025 | BUY |
Strong Buy
+7.8% avg upside
37 analysts
|
— | +9.1% |
|
KLRS
Kalaris Therapeutics
|
Sep 16, 2025 | BUY |
Buy
+170.8% avg upside
13 analysts
|
$20.00
323.70% Upside
|
-2.2% |
|
DNLI
Denali Therapeutics
|
Aug 13, 2025 | BUY |
Strong Buy
+60.2% avg upside
24 analysts
|
$40.00
71.60% Upside
|
+48.1% |
|
ALDX
Aldeyra Therapeutics
|
Aug 12, 2025 | BUY |
Strong Buy
+716.1% avg upside
21 analysts
|
$10.00
410.25% Upside
|
-68.7% |
|
DFTX
Definium Therapeutics
|
Aug 01, 2025 | BUY |
Strong Buy
+44.9% avg upside
20 analysts
|
$20.00
18.30% Downside
|
+189.5% |
|
LENZ
LENZ Therapeutics
|
Aug 01, 2025 | BUY |
Buy
+281.4% avg upside
17 analysts
|
$36.00
485.46% Upside
|
-77.2% |
|
RLMD
Relmada Therapeutics
|
May 13, 2025 | HOLD |
Buy
+106.4% avg upside
15 analysts
|
— | +1820.5% |
|
OPTEY
Opthea Limited Sponsored ADR
|
Mar 26, 2025 | HOLD |
Hold
+37213.4% avg upside
7 analysts
|
$1.00
4875.16% Upside
|
· |
|
JNJ
Johnson & Johnson
|
Jan 13, 2025 | BUY |
Strong Buy
-3.6% avg upside
36 analysts
|
— | +52.4% |
|
CLYM
Climb Bio
|
May 12, 2023 | BUY |
Strong Buy
+57.9% avg upside
18 analysts
|
$4.00
65.04% Downside
|
+164.4% |
|
ALLO
Allogene Therapeutics
|
Jan 24, 2023 | BUY |
Strong Buy
+662.8% avg upside
28 analysts
|
$24.00
1100.02% Upside
|
-60.2% |
|
IRON
Disc Medicine
|
Jul 11, 2022 | HOLD |
Strong Buy
+20.3% avg upside
21 analysts
|
$20.00
71.83% Downside
|
-4.0% |
|
CALC
CalciMedica
|
Jul 11, 2022 | HOLD |
Buy
+3672.8% avg upside
9 analysts
|
$70.00
9166.60% Upside
|
-38.4% |
|
DC
Dakota Gold Corp
|
Jun 27, 2022 | HOLD |
Strong Buy
+131.2% avg upside
5 analysts
|
— | · |
|
CRC
California Resources Corp
|
May 03, 2022 | BUY |
Strong Buy
+34.1% avg upside
19 analysts
|
— | -3.8% |
|
A
Agilent
|
May 13, 2021 | BUY |
Strong Buy
+3.9% avg upside
32 analysts
|
$25.00
80.25% Downside
|
-7.7% |
|
APA
APA
|
May 04, 2021 | BUY |
Hold
+12.2% avg upside
41 analysts
|
— | +126.3% |
|
CRL
Charles River Labs
|
Apr 05, 2021 | BUY |
Strong Buy
+12.0% avg upside
34 analysts
|
$31.00
83.32% Downside
|
-3.1% |
|
VRTX
Vertex Pharmaceuticals
|
Mar 19, 2019 | HOLD |
Strong Buy
-2.7% avg upside
61 analysts
|
— | +18.7% |
|
REGN
Regeneron
|
Nov 12, 2018 | BUY |
Strong Buy
+26.9% avg upside
57 analysts
|
$473.00
22.38% Downside
|
+0.5% |
|
BMY
Bristol-Myers Squibb
|
May 21, 2018 | HOLD |
Buy
+9.1% avg upside
42 analysts
|
$57.00
5.51% Upside
|
-6.4% |
|
VTRS
Viatris
|
Mar 01, 2018 | BUY |
Buy
+48.2% avg upside
21 analysts
|
$54.00
251.36% Upside
|
-32.5% |
|
PFE
Pfizer
|
Jan 31, 2018 | BUY |
Buy
+34.1% avg upside
45 analysts
|
$42.00
66.61% Upside
|
+19.7% |
|
TEVA
Teva Pharmaceutical
|
Dec 18, 2017 | HOLD |
Buy
-6.8% avg upside
39 analysts
|
$20.00
36.48% Downside
|
-8.2% |
|
MRK
Merck & Company
|
Oct 30, 2017 | BUY |
Strong Buy
+10.7% avg upside
43 analysts
|
$67.00
41.19% Downside
|
+37.5% |
|
ABBV
AbbVie
|
Oct 13, 2017 | HOLD |
Buy
+2.8% avg upside
43 analysts
|
$95.00
56.11% Downside
|
+3.9% |
|
PRGO
Perrigo Company
|
Oct 05, 2017 | BUY |
Buy
+565.5% avg upside
20 analysts
|
$98.00
856.11% Upside
|
-16.8% |
|
LLY
Eli Lilly & Co
|
Jul 26, 2017 | HOLD |
Strong Buy
-10.5% avg upside
47 analysts
|
$85.00
92.18% Downside
|
+19.5% |
|
AMRX
Amneal Pharmaceuticals
|
Nov 10, 2016 | SELL |
Strong Buy
+5.6% avg upside
18 analysts
|
$12.00
26.02% Downside
|
· |
|
GILD
Gilead Sciences
|
Nov 02, 2016 | BUY |
Strong Buy
-4.8% avg upside
66 analysts
|
$118.00
4.71% Downside
|
+4.7% |
|
IRWD
Ironwood Pharma
|
Jun 14, 2016 | SELL |
Hold
+235.8% avg upside
23 analysts
|
$8.00
126.00% Upside
|
-37.8% |
|
TSE:BHC
Bausch Health Companies
|
Mar 21, 2016 | BUY |
Buy
+783.6% avg upside
29 analysts
|
— | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.